The influenza virus circulates continuously, causing regional epidemics and outbreaks, leading to thousands of deaths. For instance, according to the Centers for Disease Control and Prevention (CDC) data statistics, more than 13 million flu cases were recorded so far in the 2019-20 timeframe. The changing character of the virus is compelling an annual change in the vaccine strain to match the influenza virus strain worldwide. The increasing prevalence of influenza epidemics and seasonal outbreaks is likely to expand the product sales during the projected period. There are numerous licensed seasonal influenza vaccines recommended by the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and other governmental organizations to help fight the disease in the current market scenario. Governments have focused on advising people to get vaccinated early to provide maximum protection during the flu season. Moreover, pharmaceutical companies are continually facing new challenges in developing a suitable vaccine against a particular strain. Therefore, the rising demand for effective flu vaccines is anticipated to surge the global market. The coronavirus pandemic naturally impacted the routine immunization programs and campaigns conducted worldwide in developing and developed countries. However, Flu vaccination rates have gone up considerably during the pandemic owing to factors such as push from health experts/health departments as well as extension/expansion of various government programs that provide free vaccination against the flu. Additionally, growing awareness among the public about the higher risk of getting infected with COVID-19 if the flu weakens the immune system is also another factor contributing to the uptake of flu vaccines. For instance, according to the Centers for Disease Control & Prevention (CDC), as of May, over 189.4 million flu vaccines for the 2020-2021 flu season have been distributed in the U.S compared to 174 million in the 2019-2020 season. Growing prevalence of influenza disease worldwide has led to implementation of different strategies by the government to boost the uptake of flu vaccine in the countries. One of the crucial strategy in the inclusion of the vaccine in the immunization program of the countries specifically focusing on the emerging and low-income economies. Nowadays, owing to the greater awareness among the population with respect to infectious diseases has led to timely vaccination in the developing countries. Developing countries have revised their immunization programs and included compulsory flu vaccination in the annual program for all age groups. For instance, the Singapore government has established a National Childhood Immunization Schedule (NCIS) in 2017 under the Ministry of Health that comprises of immunization against 12 diseases. In November 2020, the NCIS announced the inclusion of vaccination for influenza and varicella. Such initiatives is anticipated to rise the demand for flu vaccine resulting in strong market growth during the forecast period.